Course Detail

This practice program is undergoing essential updates related to the JNC VIII changes. Look for updates soon.

Dyslipidemia is one of the major risk factors for coronary artery disease, stroke, and peripheral vascular disease. Strategies for primary and secondary prevention have been developed and published by panels of experts and are intended to serve as guidelines for management of patients at various levels of risk for cardiovascular disease development. This course reviews the guidelines for pharmacologic management of dyslipidemia in the general and at risk populations. In addition, recently published landmark trials related to pharmacologic management are reviewed and placed into the perspective of the current guidelines.

Learning Objectives

1. State the therapeutic objectives associated with primary and secondary prevention of dyslipidemia;
2. List patient and agent related variables for the drugs used to manage dyslipidemia;
3. Perform a risk stratification to determine goals for dyslipidemia therapy; and
4. State the implications for statin induced diabetes.

CE: 2.0 Contact Hours
Universal Activity Number (UAN): 0025-0000-13-009-H01-P
Expiration Date: 1/14/2016
Course Number: KE-CN#CVD001
Instructor: David S. Roffman, PharmD, BCPS/Cardiology, Professor, University of Maryland School of Pharmacy
Fee: $50.00


This course is sponsored in part by an educational grant from the Maryland Department of Health and Mental Hygiene and the Institute for a Healthiest Maryland.

Click here for additional course details.